Pegvaliase

Pegvaliase
Clinical data
Trade names	Palynziq
Other names	Pegvaliase-pqpz; PEG-PAL; RAvPAL-PEG
Routes of; administration	Subcutaneous injection
ATC code	None;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name (2S)-2-amino-6-[6-(2-methoxyethoxy)hexanamido]hexanoic acid;
CAS Number	1585984-95-7;
PubChem CID	86278362;
DrugBank	DB12839;
ChemSpider	58172730;
UNII	N6UAH27EUV;
KEGG	D11077;
Chemical and physical data
3D model (JSmol)	Interactive image;
	SMILES COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O;
	InChI InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1; Key:NPOCDVAOUKODSQ-ZDUSSCGKSA-N;

Pegvaliase (trade name Palynziq) is a medication for the treatment of the genetic disease phenylketonuria.[1] Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.[2]

It was approved by the Food and Drug Administration for use in the United States in 2018.[1]

References

"FDA approves a new treatment for PKU, a rare and serious genetic disease". Food and Drug Administration. May 24, 2018.
"Palynziq". BioMarin Pharmaceutica.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[FDA2018Sub-1] "FDA approves a new treatment for PKU, a rare and serious genetic disease". Food and Drug Administration. May 24, 2018.

[2] "Palynziq". BioMarin Pharmaceutica.